



Journal Website:
<https://theusajournals.com/index.php/ijmscr>

Copyright: Original
content from this work
may be used under the
terms of the creative
commons attributes
4.0 licence.



ASSESSING THE EFFECTIVENESS OF EXTRACORPOREAL SHOCKWAVE THERAPY FOR MYOFASCIAL PAIN SYNDROME IN THE UPPER TRAPEZIUS

Submission Date: May 22, 2024, Accepted Date: May 27, 2024,

Published Date: June 01, 2024

Shruti Agarwal

Department of Physiotherapy, S.B.B. College of Physiotherapy, V S General Hospital, Ahmedabad, Gujarat, India

ABSTRACT

Myofascial Pain Syndrome (MPS) in the upper trapezius muscle is a common and often debilitating condition characterized by the presence of trigger points and associated pain. This study aims to evaluate the effectiveness of Extracorporeal Shockwave Therapy (ESWT) as a treatment modality for MPS in the upper trapezius. A randomized controlled trial was conducted with participants diagnosed with MPS. Subjects were divided into two groups: the treatment group received ESWT, while the control group received a placebo treatment. Outcome measures included pain intensity, assessed using the Visual Analog Scale (VAS), and functional disability, measured by the Neck Disability Index (NDI). Results indicated a significant reduction in pain intensity and improvement in functional disability in the ESWT group compared to the control group. These findings suggest that ESWT is an effective therapeutic option for reducing pain and improving function in patients with MPS of the upper trapezius.

KEYWORDS

Extracorporeal Shockwave Therapy (ESWT), Myofascial Pain Syndrome (MPS), Upper Trapezius, Trigger Points, Pain Management, Visual Analog Scale (VAS), Neck Disability Index (NDI), Randomized Controlled Trial (RCT), Rehabilitation.

INTRODUCTION

Myofascial Pain Syndrome (MPS) is a prevalent musculoskeletal condition characterized by chronic pain, muscle stiffness, and the presence of myofascial trigger points (MTrPs). These hyperirritable nodules within taut bands of skeletal muscle fibers are a primary source of pain and dysfunction, often leading to significant impairment in daily activities. Among the various muscles affected, the upper trapezius muscle is particularly prone to developing MPS, primarily due to its extensive use and susceptibility to stress and strain.

Traditional treatment modalities for MPS in the upper trapezius include physical therapy, manual therapy, pharmacological interventions, and various forms of dry needling. Despite these approaches, many patients continue to experience persistent pain and functional limitations, highlighting the need for alternative and more effective treatment options. In recent years, Extracorporeal Shockwave Therapy (ESWT) has emerged as a promising non-invasive treatment modality for various musculoskeletal disorders, including MPS.

ESWT involves the application of acoustic waves to the affected tissue, promoting pain relief and tissue regeneration through mechanical and biological effects. These effects include increased local blood flow, reduction of muscle tone, and modulation of inflammatory processes. Although ESWT has shown

positive outcomes in treating conditions such as plantar fasciitis and calcific tendinitis, its efficacy in managing MPS of the upper trapezius remains underexplored.

This study aims to assess the effectiveness of ESWT in treating MPS in the upper trapezius muscle. By conducting a randomized controlled trial, we seek to determine whether ESWT can significantly reduce pain intensity and improve functional disability compared to placebo treatment. The findings of this study could provide valuable insights into the potential role of ESWT as a viable treatment option for patients suffering from MPS in the upper trapezius, ultimately contributing to improved patient care and quality of life.


METHODS

A comprehensive search was performed using several electronic databases, including PubMed, Cochrane Library, Embase, and Scopus, from 2010 to 2022. The search strategy included a combination of keywords related to ESWT, MPS, and upper trapezius. Additionally, a manual search of relevant journals was conducted. Studies were included if they met the following criteria: (1) randomized controlled trials, (2) non-randomized controlled trials, (3) prospective cohort studies, or (4) case series, (5) studies that evaluated the efficacy of ESWT in the treatment of

MPS of the upper trapezius. The Cochrane Risk of Bias tool was used to assess the methodological quality of the included studies.

The objective of this systematic review is to explore the impact of extracorporeal shockwave therapy (ESWT)

on myofascial pain syndrome (MPS) of the upper trapezius. The review aims to provide a comprehensive analysis of the available literature on the efficacy and effectiveness of ESWT in treating MPS of the upper trapezius.



A systematic and comprehensive search strategy was developed to identify relevant studies. The following electronic databases were searched: PubMed, Cochrane Library, Embase, and Scopus. The search terms included a combination of keywords related to ESWT, MPS, and upper trapezius. Additionally, a manual search of relevant journals and reference lists of identified articles was conducted to ensure the inclusion of all relevant studies.

Inclusion criteria:


- Published studies between 2010 and 2022.

- Studies that evaluated the efficacy of ESWT in the treatment of MPS of the upper trapezius.
- Study designs: randomized controlled trials, non-randomized controlled trials, prospective cohort studies, or case series.
- Studies reporting outcomes related to pain reduction, functional improvement, or other relevant measures.

Exclusion criteria:

- Studies not related to ESWT or MPS of the upper trapezius.
- Animal studies, reviews, case reports, or editorials.

Two independent reviewers screened the titles, abstracts, and full texts of the identified articles based on the inclusion and exclusion criteria. Any discrepancies between the reviewers were resolved through discussion and consensus.



PUBLISHING SERVICES

Data extraction was performed by two independent reviewers using a predefined data extraction form. The following information was extracted from each study: study characteristics (e.g., author, year, country), participant characteristics, intervention details (ESWT parameters), outcome measures, results, and adverse events.

The methodological quality and risk of bias assessment of the included studies were conducted using the Cochrane Risk of Bias tool for randomized controlled trials and the Newcastle-Ottawa Scale for non-

randomized studies. Any disagreements in quality assessment were resolved through discussion and consensus.

A narrative synthesis approach was used to summarize the findings of the included studies. The extracted data were analyzed qualitatively, focusing on the outcomes related to pain reduction, functional improvement, and adverse events. The results were presented in a descriptive manner, highlighting the key findings and trends across the studies.

The limitations of the included studies and potential sources of bias were discussed and considered in the interpretation of the results. The limitations included heterogeneity among study designs, variations in ESWT parameters, small sample sizes, and the potential for publication bias.

RESULTS

A total of 15 studies met the inclusion criteria and were included in the systematic review. The studies involved a total of 782 participants, with sample sizes ranging from 14 to 130. The duration of follow-up ranged from 1 week to 6 months. The quality of evidence was assessed as moderate to low, due to the heterogeneity of the studies and the small sample sizes. The majority of the studies reported a significant reduction in pain and improvement in function following ESWT, compared to placebo or other active treatments. However, the effect size and duration of the effect varied between studies. No significant adverse events were reported.

DISCUSSION

The results of this systematic review suggest that ESWT is a promising treatment option for MPS of the upper trapezius, with a significant reduction in pain and improvement in function reported in most studies. However, the quality of evidence is limited by the heterogeneity of the included studies and the small sample sizes. The optimal dosage, frequency, and

duration of ESWT treatment remain unclear. Additionally, the long-term effects of ESWT on MPS of the upper trapezius are yet to be determined. Further research with larger sample sizes, longer follow-up periods, and more rigorous study designs is needed to establish the effectiveness of ESWT for MPS of the upper trapezius and to optimize its clinical application.

CONCLUSION

Based on the available evidence, ESWT appears to be a promising treatment option for MPS of the upper trapezius, with a significant reduction in pain and improvement in function reported in most studies. However, the quality of evidence is limited by the heterogeneity of the included studies and the small sample sizes. Further research is needed to establish the optimal dosage, frequency, and duration of ESWT treatment, as well as to determine the long-term effects of ESWT on MPS of the upper trapezius. Clinicians should consider the potential benefits of ESWT as part of a multimodal treatment approach for MPS of the upper trapezius, while taking into account the individual patient characteristics and preferences.

REFERENCES

1. Chow RT, Barnsley L. Systematic review of the literature of low-level laser therapy (LLLT) in the management of neck pain. *Lasers Surg Med* 2005;37:46-52.

2. Shah JP, Danoff JV, Desai MJ, Parikh S, Nakamura LY, Phillips TM, et al. Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points. *Arch Phys Med Rehabil* 2008;89:16-23.
3. Shah JP, Gilliams EA. Uncovering the biochemical milieu of myofascial trigger points using in vivo microdialysis: An application of muscle pain concepts to myofascial pain syndrome. *J Bodyw Mov Ther* 2008;12:371-84.
4. Cerezo-Téllez E, Torres-Lacomba M, Mayoral-Del Moral O, Sánchez-Sánchez B, Dommerholt J, Gutiérrez-Ortega C. Prevalence of myofascial pain syndrome in chronic non-specific neck pain: A population-based cross-sectional descriptive study. *Pain Med* 2016;17:2369-77.
5. Bron C, Dommerholt JD. Etiology of myofascial trigger points. *Curr Pain Headache Rep* 2012;16:439-44.
6. International Society for Medical Shockwave Treatment. ESWT-Basic Physical Principals. Vienna, Austria: International Society for Medical Shockwave Treatment; 2016.
7. Moya D, Ramón S, Schaden W, Wang CJ, Guilloff L, Cheng JH. The role of extracorporeal shockwave treatment in musculoskeletal disorders. *J Bone Joint Surg Am* 2018;100:251-63.
8. Yoo JI, Oh MK, Chun SW, Lee SU, Lee CH. The effect of focused extracorporeal shock wave therapy on myofascial pain syndrome of trapezius: A systematic review and meta-analysis. *Medicine (Baltimore)* 2020;99:e19085.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* 2009;338:b2535.
10. Riva JJ, Malik KM, Burnie SJ, Endicott AR, Busse JW. What is your research question? An introduction to the PICOT format for clinicians. *J Can Chiropr Assoc* 2012;56:167-71.
11. Ji HM, Kim HJ, Han SJ. Extracorporeal shock wave therapy in myofascial pain syndrome of upper trapezius. *Ann Rehabil Med* 2012;36:675-80.
12. Gür A, Koca I, Karagüllü H, Altındağ Ö, Madenci E, Tutoğlu A, et al. Comparison of the effectiveness of two different extracorporeal shock wave therapy regimens in the treatment of patients with myofascial pain syndrome. *Arch Rheumatol* 2014;29:186-93.
13. Yanga YJ, Leeb SJ, Choi M. Pressure pain threshold and visual analogue scale changes in the high and low energy extracorporeal shock wave. *Phys Ther Rehabil Sci* 2014;3:142-7.